ES2613055T3 - Diagnóstico de interferón de tipo 1 - Google Patents
Diagnóstico de interferón de tipo 1 Download PDFInfo
- Publication number
- ES2613055T3 ES2613055T3 ES10814513.7T ES10814513T ES2613055T3 ES 2613055 T3 ES2613055 T3 ES 2613055T3 ES 10814513 T ES10814513 T ES 10814513T ES 2613055 T3 ES2613055 T3 ES 2613055T3
- Authority
- ES
- Spain
- Prior art keywords
- ifnα
- type
- genes
- ifi44
- rsad2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FBBUFUYJOZFZPJ-UHFFFAOYSA-N C(CC1)CC1C(CC1)CC1C(CC1)CCC1C(CC1)CCC1C1CCCC1 Chemical compound C(CC1)CC1C(CC1)CC1C(CC1)CCC1C(CC1)CCC1C1CCCC1 FBBUFUYJOZFZPJ-UHFFFAOYSA-N 0.000 description 1
- 0 CC1C(*)CCC1 Chemical compound CC1C(*)CCC1 0.000 description 1
- UKCAQUQDAABMJQ-UHFFFAOYSA-N CC1CC(CC2)=C2C1 Chemical compound CC1CC(CC2)=C2C1 UKCAQUQDAABMJQ-UHFFFAOYSA-N 0.000 description 1
- XARGIVYWQPXRTC-UHFFFAOYSA-N CCC1C(C)CCCC1 Chemical compound CCC1C(C)CCCC1 XARGIVYWQPXRTC-UHFFFAOYSA-N 0.000 description 1
- GURKWNMOHNXWGJ-UHFFFAOYSA-N CCCCCCCC(CCC1)CC1C(CC1)CCC1C(CCC)CCC(CC1)CC1C(CC1)CCC1C1CC(C)CCC1 Chemical compound CCCCCCCC(CCC1)CC1C(CC1)CCC1C(CCC)CCC(CC1)CC1C(CC1)CCC1C1CC(C)CCC1 GURKWNMOHNXWGJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23963009P | 2009-09-03 | 2009-09-03 | |
| US239630P | 2009-09-03 | ||
| PCT/US2010/047721 WO2011028933A1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2613055T3 true ES2613055T3 (es) | 2017-05-22 |
Family
ID=43649646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10814513.7T Active ES2613055T3 (es) | 2009-09-03 | 2010-09-02 | Diagnóstico de interferón de tipo 1 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120251546A1 (https=) |
| EP (1) | EP2473636B1 (https=) |
| JP (2) | JP5727484B2 (https=) |
| KR (1) | KR20120101340A (https=) |
| CN (1) | CN102753704A (https=) |
| AU (1) | AU2010289383B2 (https=) |
| BR (1) | BR112012004781A2 (https=) |
| CA (1) | CA2772921A1 (https=) |
| CY (1) | CY1118566T1 (https=) |
| DK (1) | DK2473636T3 (https=) |
| ES (1) | ES2613055T3 (https=) |
| HR (1) | HRP20170091T1 (https=) |
| HU (1) | HUE032917T2 (https=) |
| LT (1) | LT2473636T (https=) |
| ME (1) | ME02599B (https=) |
| MX (1) | MX2012002640A (https=) |
| PL (1) | PL2473636T3 (https=) |
| PT (1) | PT2473636T (https=) |
| RS (1) | RS55641B1 (https=) |
| RU (1) | RU2012112802A (https=) |
| SI (1) | SI2473636T1 (https=) |
| SM (2) | SMT201700063T1 (https=) |
| WO (1) | WO2011028933A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2488632A1 (en) * | 2002-06-11 | 2003-12-18 | Idaho Research Foundation | Type i interferon-inducible proteins to detect viral infection |
| EP2712930A3 (en) * | 2006-12-06 | 2014-04-23 | MedImmune, LLC | Interferon alpha-induced pharmacodynamic markers |
| CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| KR20140048877A (ko) * | 2011-04-26 | 2014-04-24 | 제넨테크, 인크. | 자가면역 질환의 치료를 위한 조성물 및 방법 |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| KR102320059B1 (ko) | 2012-06-13 | 2021-11-01 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
| JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
| CN105316404B (zh) * | 2015-02-27 | 2017-02-22 | 中南大学湘雅二医院 | 系统性红斑狼疮生物标志物及其诊断试剂盒 |
| AU2017231833B2 (en) | 2016-03-10 | 2024-03-14 | Viela Bio, Inc. | ILT7 binding molecules and methods of using the same |
| CN105567861B (zh) * | 2016-03-16 | 2018-12-14 | 宫蕊 | Ifi27作为冠心病诊断标志物的用途 |
| SG11202108679PA (en) * | 2019-02-15 | 2021-09-29 | Astrazeneca Ab | Type i interferon-mediated disorders |
| EP4494712A3 (en) | 2019-11-11 | 2025-03-26 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
| EP4157873A2 (en) | 2020-05-29 | 2023-04-05 | Astrazeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| JP2023544351A (ja) * | 2020-10-02 | 2023-10-23 | セルジーン コーポレーション | 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| WO2022106460A2 (en) | 2020-11-18 | 2022-05-27 | Astrazeneca Ab | Steroid sparing |
| CA3216395A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| CA3216390A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of cutaneous lupus erythematous |
| CN120392997A (zh) | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| MX2023013015A (es) * | 2021-05-04 | 2023-11-15 | Viela Bio Inc | Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7). |
| IL308128A (en) | 2021-05-12 | 2023-12-01 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
| KR20240038773A (ko) | 2021-07-27 | 2024-03-25 | 아스트라제네카 아베 | 루푸스의 치료 |
| JP2024536320A (ja) | 2021-10-04 | 2024-10-04 | アストラゼネカ・アクチエボラーグ | ループスの処置 |
| IL319505A (en) | 2022-09-14 | 2025-05-01 | Viatris Asia Pacific Pte Ltd | S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon |
| CN120344259A (zh) | 2022-10-13 | 2025-07-18 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| AU2024277546A1 (en) | 2023-05-19 | 2026-01-15 | Astrazeneca Ab | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US7247425B2 (en) * | 1998-01-30 | 2007-07-24 | Evolutionary Genomics, Llc | Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US7749695B2 (en) * | 2003-03-03 | 2010-07-06 | Alexander Abbas | PRO polypeptides for diagnosis of systemic lupus erythematosis |
| CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| JP2007525458A (ja) | 2003-04-23 | 2007-09-06 | メダレックス インコーポレイテッド | インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体 |
| KR101225299B1 (ko) | 2003-12-10 | 2013-01-24 | 메다렉스, 인코포레이티드 | 인터페론 알파 항체 및 그의 용도 |
| JP2007527247A (ja) * | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類 |
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| DK2327792T3 (da) * | 2005-08-05 | 2014-01-13 | Genentech Inc | Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme |
| WO2007123765A2 (en) * | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| EP2052088A2 (en) * | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| EP2712930A3 (en) * | 2006-12-06 | 2014-04-23 | MedImmune, LLC | Interferon alpha-induced pharmacodynamic markers |
| CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| KR20110005783A (ko) * | 2008-02-08 | 2011-01-19 | 메디뮨 엘엘씨 | 질환 마커 및 그의 용도 |
| US20110117563A1 (en) * | 2008-04-21 | 2011-05-19 | Witold Filipowicz | Antiviral therapy |
| WO2009149319A2 (en) * | 2008-06-05 | 2009-12-10 | Wyeth | Gene expression profiles associated with asthma exacerbation attacks |
-
2010
- 2010-09-02 CA CA2772921A patent/CA2772921A1/en not_active Abandoned
- 2010-09-02 SI SI201031376A patent/SI2473636T1/sl unknown
- 2010-09-02 ES ES10814513.7T patent/ES2613055T3/es active Active
- 2010-09-02 BR BR112012004781A patent/BR112012004781A2/pt not_active IP Right Cessation
- 2010-09-02 SM SM20170063T patent/SMT201700063T1/it unknown
- 2010-09-02 US US13/393,616 patent/US20120251546A1/en not_active Abandoned
- 2010-09-02 WO PCT/US2010/047721 patent/WO2011028933A1/en not_active Ceased
- 2010-09-02 MX MX2012002640A patent/MX2012002640A/es not_active Application Discontinuation
- 2010-09-02 RS RS20170089A patent/RS55641B1/sr unknown
- 2010-09-02 LT LTEP10814513.7T patent/LT2473636T/lt unknown
- 2010-09-02 HU HUE10814513A patent/HUE032917T2/hu unknown
- 2010-09-02 PT PT108145137T patent/PT2473636T/pt unknown
- 2010-09-02 HR HRP20170091TT patent/HRP20170091T1/hr unknown
- 2010-09-02 CN CN2010800447566A patent/CN102753704A/zh active Pending
- 2010-09-02 JP JP2012528058A patent/JP5727484B2/ja not_active Expired - Fee Related
- 2010-09-02 ME MEP-2017-24A patent/ME02599B/me unknown
- 2010-09-02 AU AU2010289383A patent/AU2010289383B2/en not_active Ceased
- 2010-09-02 DK DK10814513.7T patent/DK2473636T3/en active
- 2010-09-02 PL PL10814513T patent/PL2473636T3/pl unknown
- 2010-09-02 RU RU2012112802/10A patent/RU2012112802A/ru not_active Application Discontinuation
- 2010-09-02 KR KR1020127008547A patent/KR20120101340A/ko not_active Withdrawn
- 2010-09-02 EP EP10814513.7A patent/EP2473636B1/en active Active
-
2015
- 2015-03-18 US US14/662,134 patent/US20150191788A1/en not_active Abandoned
- 2015-04-02 JP JP2015075518A patent/JP2015147788A/ja active Pending
- 2015-10-06 US US14/876,549 patent/US20160024205A1/en not_active Abandoned
-
2017
- 2017-01-26 SM SM201700063T patent/SMT201700063B/it unknown
- 2017-01-26 CY CY20171100112T patent/CY1118566T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150191788A1 (en) | 2015-07-09 |
| SI2473636T1 (sl) | 2017-04-26 |
| DK2473636T3 (en) | 2017-02-06 |
| HRP20170091T1 (hr) | 2017-03-24 |
| CN102753704A (zh) | 2012-10-24 |
| EP2473636A1 (en) | 2012-07-11 |
| PT2473636T (pt) | 2017-02-06 |
| US20120251546A1 (en) | 2012-10-04 |
| PL2473636T3 (pl) | 2017-05-31 |
| JP2015147788A (ja) | 2015-08-20 |
| WO2011028933A1 (en) | 2011-03-10 |
| RS55641B1 (sr) | 2017-06-30 |
| MX2012002640A (es) | 2012-06-25 |
| KR20120101340A (ko) | 2012-09-13 |
| EP2473636B1 (en) | 2016-10-26 |
| AU2010289383B2 (en) | 2015-04-16 |
| BR112012004781A2 (pt) | 2017-02-14 |
| RU2012112802A (ru) | 2013-10-10 |
| CA2772921A1 (en) | 2011-03-10 |
| AU2010289383A1 (en) | 2012-04-19 |
| CY1118566T1 (el) | 2017-07-12 |
| HUE032917T2 (hu) | 2017-11-28 |
| EP2473636A4 (en) | 2013-02-27 |
| SMT201700063B (it) | 2017-03-08 |
| LT2473636T (lt) | 2017-02-10 |
| US20160024205A1 (en) | 2016-01-28 |
| JP2013503642A (ja) | 2013-02-04 |
| JP5727484B2 (ja) | 2015-06-03 |
| SMT201700063T1 (it) | 2017-03-08 |
| ME02599B (me) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2613055T3 (es) | Diagnóstico de interferón de tipo 1 | |
| Atreya et al. | Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? | |
| JP5411129B2 (ja) | インターフェロンα誘導性薬力学的マーカー | |
| KR101532797B1 (ko) | 인터페론 알파 유도성 약력학적 마커 | |
| ES2529593T3 (es) | Marcadores de enfermedades y usos de los mismos | |
| US20110287022A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| CN101594882A (zh) | 干扰素α诱导的药代动力学标记物 | |
| Okumura et al. | Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells | |
| CN113508138B (zh) | I型干扰素介导的障碍 | |
| US20100261172A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| WO2009155559A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| AU2014200127A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| AU2014200128A1 (en) | Interferon alpha-induced pharmacodynamic markers |